$TVTX
Travere Therapeutics, Inc. Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000143853323000008 Filed on February 23, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$56.99M	$55.87M	$212.0M
YoY Change	17.54%	-2.41%	-6.8%
Cost Of Revenue	$5.125M	$1.728M	$7.592M
YoY Change	139.71%	-8.86%	11.91%
Gross Profit	$51.87M	$54.14M	$204.4M
YoY Change	11.91%	-2.19%	-7.38%
Gross Profit Margin	91.01%	96.91%	96.42%
Selling, General & Admin	$72.25M	$56.60M	$220.2M
YoY Change	54.41%	57.86%	46.92%
% of Gross Profit	139.29%	104.54%	107.72%
Research & Development	$7.500M	$57.79M	$7.500M
YoY Change	-86.75%	-6.61%	-96.43%
% of Gross Profit	14.46%	106.73%	3.67%
Depreciation & Amortization	$9.545M	$9.301M	$33.08M
YoY Change	34.59%	53.74%	24.28%
% of Gross Profit	18.4%	17.18%	16.18%
Operating Expenses	$79.75M	$121.0M	$227.7M
YoY Change	-22.88%	17.99%	-36.79%
Operating Profit	-$87.05M	-$66.85M	-$266.6M
YoY Change	31.63%	41.66%	64.79%
Interest Expense	$2.900M	$219.0K	$11.30M
YoY Change	-215.31%	-104.53%	-43.78%
% of Operating Profit
Other Income/Expense, Net	$793.0K	$872.0K	-$11.60M
YoY Change	-108.1%	92.07%	-35.24%
Pretax Income	-$86.25M	-$65.76M	-$278.2M
YoY Change	13.61%	27.52%	54.81%
Income Tax	$78.00K	$63.00K	$313.0K
% Of Pretax Income
Net Earnings	-$86.33M	-$65.82M	-$278.5M
YoY Change	13.64%	27.63%	54.63%
Net Earnings / Revenue	-151.48%	-117.82%	-131.35%
Basic Earnings Per Share	-$1.27	-$1.03	-$4.37
Diluted Earnings Per Share	-$1.27	-$1.03	-$4.37
COMMON SHARES
Basic Shares Outstanding	64.74M shares	64.17M shares	63.76M shares
Diluted Shares Outstanding	68.17M shares		63.76M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$440.4M	$347.2M	$450.2M
YoY Change	-16.85%	-18.86%	-18.56%
Cash & Equivalents	$161.4M	$61.69M	$61.69M
Short-Term Investments	$279.1M	$285.5M	$388.6M
Other Short-Term Assets	$15.14M	$12.62M	$12.62M
YoY Change	132.7%	95.09%	95.09%
Inventory	$6.712M	$6.922M	$6.922M
Prepaid Expenses
Receivables	$21.50M	$16.65M	$16.65M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$604.9M	$486.4M	$486.4M
YoY Change	-4.15%	-16.54%	-16.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.127M	$9.049M	$30.05M
YoY Change	-13.91%	-18.52%	-12.4%
Goodwill	$900.0K	$900.0K
YoY Change	0.0%	0.0%
Intangibles	$162.9M	$145.0M
YoY Change	6.24%	-2.29%
Long-Term Investments
YoY Change
Other Assets	$11.03M	$11.06M	$11.06M
YoY Change	1.81%	-0.07%	-0.07%
Total Long-Term Assets	$203.3M	$186.1M	$186.1M
YoY Change	3.05%	-3.95%	-3.95%
TOTAL ASSETS
Total Short-Term Assets	$604.9M	$486.4M	$486.4M
Total Long-Term Assets	$203.3M	$186.1M	$186.1M
Total Assets	$808.2M	$672.6M	$672.6M
YoY Change	-2.44%	-13.4%	-13.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.73M	$17.29M	$17.29M
YoY Change	-9.26%	14.17%	14.17%
Accrued Expenses	$85.77M	$95.74M	$74.11M
YoY Change	23.87%	27.35%	41.84%
Deferred Revenue	$10.98M	$11.98M
YoY Change	-22.87%	-26.38%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$130.6M	$142.2M	$142.2M
YoY Change	9.35%	14.57%	14.57%
LONG-TERM LIABILITIES
Long-Term Debt	$376.0M	$375.5M	$375.5M
YoY Change	0.44%	65.74%	65.74%
Other Long-Term Liabilities	$9.068M	$9.385M	$112.0M
YoY Change	-12.39%	-23.55%	-9.55%
Total Long-Term Liabilities	$9.068M	$9.385M	$487.6M
YoY Change	-12.39%	-23.55%	39.13%
TOTAL LIABILITIES
Total Short-Term Liabilities	$130.6M	$142.2M	$142.2M
Total Long-Term Liabilities	$9.068M	$9.385M	$487.6M
Total Liabilities	$619.1M	$629.7M	$629.7M
YoY Change	-0.19%	32.71%	32.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.101B	-$1.014B
YoY Change	35.58%	32.41%
Common Stock	$7.000K	$6.000K
YoY Change	16.67%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$189.1M	$42.85M	$42.85M
YoY Change
Total Liabilities & Shareholders Equity	$808.2M	$672.6M	$672.6M
YoY Change	-2.44%	-13.4%	-13.4%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$86.33M	-$65.82M	-$278.5M
YoY Change	13.64%	27.63%	54.63%
Depreciation, Depletion And Amortization	$9.545M	$9.301M	$33.08M
YoY Change	34.59%	53.74%	24.28%
Cash From Operating Activities	-$81.12M	-$54.64M	-$186.3M
YoY Change	46.63%	103.3%	1159.4%
INVESTING ACTIVITIES
Capital Expenditures	$630.0K	$4.197M	$191.0K
YoY Change	380.92%	-180.71%	-96.26%
Acquisitions			$0.00
YoY Change
Other Investing Activities	-$9.072M	-$32.50M	$600.0K
YoY Change	-123.61%	-358.58%	-100.53%
Cash From Investing Activities	-$37.04M	-$36.70M	-$32.55M
YoY Change	-211.68%	-597.98%	-76.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$217.0M	551.0K	$117.6M
YoY Change	90.49%	-98.34%	-49.25%
NET CHANGE
Cash From Operating Activities	-$81.12M	-54.64M	-$186.3M
Cash From Investing Activities	-$37.04M	-36.70M	-$32.55M
Cash From Financing Activities	$217.0M	551.0K	$117.6M
Net Change In Cash	$99.69M	-90.79M	-$104.1M
YoY Change	9.77%	-762.41%	-228.51%
FREE CASH FLOW
Cash From Operating Activities	-$81.12M	-$54.64M	-$186.3M
Capital Expenditures	$630.0K	$4.197M	$191.0K
Free Cash Flow	-$81.75M	-$58.84M	-$186.5M
YoY Change	47.42%	171.43%	837.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006CumulativeEffectPeriodOfAdoptionMember
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36257
CY2022	dei	Entity Registrant Name EntityRegistrantName	TRAVERE THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3611 Valley Centre Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2022	dei	City Area Code CityAreaCode	888
CY2022	dei	Local Phone Number LocalPhoneNumber	969-7879
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	TVTX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	1538771266	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	64744990	shares
CY2022	dei	Auditor Firm AuditorFirmId	243
CY2022	dei	Auditor Name AuditorName	BDO USA, LLP
CY2022	dei	Auditor Location AuditorLocation	San Diego, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61688000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165753000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	388557000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	16646000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15914000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6922000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7313000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12624000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6718000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	486437000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	582827000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9049000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11106000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21000000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23196000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	145038000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	148435000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11061000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11069000	usd
CY2022Q4	us-gaap	Assets Assets	672585000	usd
CY2021Q4	us-gaap	Assets Assets	776633000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17290000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15144000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	95742000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	75180000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11976000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	16268000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7000000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	7400000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4433000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3908000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5722000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6188000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	142163000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	124088000	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	375545000	usd
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	226581000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	10931000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	20379000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	64200000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	59700000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	27510000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31497000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9385000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	12276000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	629734000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	474521000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	64290570	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64290570	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	62491498	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62491498	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1059975000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1068634000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1014223000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-765966000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2907000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-562000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	42851000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	302112000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	672585000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	776633000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212018000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	227490000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	198321000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7592000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6784000	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6126000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	235780000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	210328000	usd
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	131773000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	220206000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	149883000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	135799000	usd
CY2022	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	15006000	usd
CY2021	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	22260000	usd
CY2020	tvtx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	3655000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	97131000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	478584000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	389255000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	374484000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-266566000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-161765000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-176163000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	6276000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1993000	usd
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	5003000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11275000	usd
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-20141000	usd
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-19050000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	974000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	231000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1420000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7578000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11603000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-17917000	usd
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-12627000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-278169000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-179682000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-188790000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	313000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	409000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19359000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-278482000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180091000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-169431000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.37
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.37
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.01
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.01
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.56
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.56
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63758515	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63758515	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59832287	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59832287	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47539631	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47539631	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-278482000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180091000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-169431000	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	368000	usd
CY2021	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2020	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	507000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1515000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1452000	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-2484000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-1175000	usd
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-176000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-280827000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-179751000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-171059000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	22733000	usd
CY2020	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	3895000	usd
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2928000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1452000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-176000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-169431000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	211213000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	29862000	usd
CY2021	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	12841000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3012000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1515000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1175000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180091000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	302112000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	37897000	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	4585000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4259000	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	368000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	507000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2484000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-278482000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	42851000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-278482000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-180091000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-169431000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33079000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26617000	usd
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24579000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	39177000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	30766000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	23614000	usd
CY2022	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	15006000	usd
CY2021	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	22260000	usd
CY2020	tvtx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	3655000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-8602000	usd
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-14375000	usd
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-12407000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7578000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	2455000	usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2110000	usd
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	2225000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1622000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11242000	usd
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	10478000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	usd
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	97131000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-972000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-6700000	usd
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3455000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	682000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	59000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2301000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2064000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1815000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5067000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	374000	usd
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-17099000	usd
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	15746000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4908000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1438000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4314000	usd
CY2022	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	-984000	usd
CY2021	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	5577000	usd
CY2020	tvtx	Change In Lease Assets And Liabilities Net ChangeInLeaseAssetsAndLiabilitiesNet	-1203000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2307000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2770000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6036000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	22261000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	18308000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4417000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-12929000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	38300000	usd
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1723000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1237000	usd
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-394000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-186291000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14792000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42743000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	381993000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	433604000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	273482000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	385389000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	547076000	usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	214964000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	191000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5101000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6767000	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	28366000	usd
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	19050000	usd
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	17799000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	95279000	usd
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	600000	usd
CY2021	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2020	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32553000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-137623000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-61327000	usd
CY2022	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2100000	usd
CY2021	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2100000	usd
CY2020	tvtx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2100000	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	2479000	usd
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	6104000	usd
CY2020	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	7648000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	316250000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9882000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	211324000	usd
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4585000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12841000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3895000	usd
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2978000	usd
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2112000	usd
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2046000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	117573000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	231683000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	127713000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-2794000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1713000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1307000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-104065000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	80981000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	22336000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165753000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84772000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61688000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	165753000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84772000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	6020000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	2205000	usd
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2537000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	10159000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7327000	usd
CY2020	us-gaap	Interest Paid Net InterestPaidNet	6901000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	996000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-16420000	usd
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-3373000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100000	usd
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1900000	usd
CY2022	tvtx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	16067000	usd
CY2021	tvtx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	19362000	usd
CY2020	tvtx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	18168000	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="margin-bottom:3pt;margin-top:12pt;text-align:justify"><span style="color:#00497f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">unmet medical need</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> and that we believe offer attractive growth characteristics.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#00497f;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FILSPARI™ (sparsentan)</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On February 17, 2023, the FDA granted accelerated approval of FILSPARI™ (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally at UPCR ≥1.5 gram/gram. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways in the disease progression of IgAN (endothelin 1 and angiotensin-II).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">Clinical-Stage Programs:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Sparsentan remains a novel investigational product candidate which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis (FSGS) in the U.S. and Europe. Evaluation of sparsentan is ongoing in two pivotal Phase 3 clinical studies in rare kidney diseases.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pegtibatinase (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">TVT-058) is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Pegtibatinase has been granted Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations by the FDA, as well as orphan drug designation in the United States and European Union. Pegtibatinase is currently being evaluated in the Phase 1/2 COMPOSE Study to assess its safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effects in patients with classical HCU. The Company</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> acquired pegtibatinase as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Chenodal (chenodeoxycholic acid or CDCA) is a naturally occurring bile acid that is approved for the treatment of people with radiolucent stones in the gallbladder. In September 2022, we were granted Fast Track Designation by the FDA for the investigation of Chenodal for cerebrotendinous xanthomatosis (CTX). In January 2020, we randomized the first patients in our Phase 3 RESTORE Study to evaluate the effects of Chenodal in adult and pediatric patients with CTX, and the study enrollment remains open. The pivotal study is intended to support an NDA submission for marketing authorization of Chenodal for CTX in the United States. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company is a participant in a Cooperative Research and Development Agreement ("CRADA"), which forms a multi-stakeholder approach to pool resources with leading experts, and incorporate the patient perspective early in the therapeutic identification and development process. The Company is partnering with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and a leading patient advocacy organization, Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for Alagille syndrome ("ALGS"). There are no treatment options currently approved for ALGS.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Arial',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">Other Commercial Products:</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:15.28pt">Thiola</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> and Thiola EC</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</span></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:15.28pt">Cholbam</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:6.17pt;font-weight:400;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div>•Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#00497f;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include revenue recognition, forecasting probability-weighted cash flows based upon estimates of forecasted revenues, clinical and regulatory timelines and discount rates, valuing equity securities in share-based payments, estimating expenses of contracted research organizations, estimating reserves for inventory, estimating the useful lives of depreciable and amortizable assets, goodwill impairment, estimating the fair value of contingent consideration, estimating of valuation allowances and uncertain tax positions, and estimates associated with the assessment of impairment for long-lived assets.</span></div>
CY2022Q4	tvtx	Increase Decreased In Research And Development Expenses And Related Accrued Expenses IncreaseDecreasedInResearchAndDevelopmentExpensesAndRelatedAccruedExpenses	-7700000	usd
CY2022	tvtx	Increase Decreased In Research And Development Expenses And Related Accrued Expenses IncreaseDecreasedInResearchAndDevelopmentExpensesAndRelatedAccruedExpenses	-1500000	usd
CY2021	tvtx	Increase Decreased In Research And Development Expenses And Related Accrued Expenses IncreaseDecreasedInResearchAndDevelopmentExpensesAndRelatedAccruedExpenses	-6200000	usd
CY2022	tvtx	Number Of Phase One Half Clinical Trials NumberOfPhaseOneHalfClinicalTrials	1	clinicaltrial
CY2022	tvtx	Number Of Phase Three Clinical Trials NumberOfPhaseThreeClinicalTrials	3	clinicaltrial
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#00497f;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company maintains its cash and cash equivalents at insured financial institutions, the balances of which may, at times, exceed federally insured limits. Generally, these deposits may be redeemed upon demand, and the Company believes there is minimal risk of losses on such balances.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company monitors its investments with counterparties with the objective of minimizing concentrations of credit risk. The Company's investment policy is to invest only in institutions that meet high credit quality standards and established limits on the amount and time to maturity of investments with any individual counterparty. The policy also requires that investments are only entered into with corporate and financial institutions that meet high quality standards.</span></div>
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3500000	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4100000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3627000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5205000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3295000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2108000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6922000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	7313000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7500000	usd
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	1400000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	300000	usd
CY2020	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	1200000	usd
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#00497f;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the prior year financial statements in order to conform to the current year’s presentation, including reclassifying operating lease right of use assets and operating lease liabilities from other assets and other liabilities, respectively on the Consolidated Balance Sheets. These reclassifications did not have an impact on total assets or total liabilities of the Consolidated Balance Sheets.</span></div>
CY2022	us-gaap	Revenue Performance Obligation Description Of Timing RevenuePerformanceObligationDescriptionOfTiming	The Company receives payments from its product sales, primarily through third party payers, based on terms that generally are within 30 days of delivery of product to the patient.
CY2022	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	800000	usd
CY2021	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	400000	usd
CY2020	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	400000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	36647000	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022	tvtx	Contract With Customer Liability New Consideration Resulting In Deferred Revenue ContractWithCustomerLiabilityNewConsiderationResultingInDeferredRevenue	0	usd
CY2021	tvtx	Contract With Customer Liability New Consideration Resulting In Deferred Revenue ContractWithCustomerLiabilityNewConsiderationResultingInDeferredRevenue	55000000	usd
CY2022	tvtx	Contract With Customer Liability Foreign Currency Impact ContractWithCustomerLiabilityForeignCurrencyImpact	-2250000	usd
CY2021	tvtx	Contract With Customer Liability Foreign Currency Impact ContractWithCustomerLiabilityForeignCurrencyImpact	-1639000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	22907000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	36647000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	388557000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2022Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	287615000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	2000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	2091000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	285526000	usd
CY2022Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	103897000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	39000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	905000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	103031000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	391512000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	41000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2996000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	388557000	usd
CY2021Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	262345000	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	159000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	262186000	usd
CY2021Q4	tvtx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	125254000	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	0	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	311000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	124943000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	387599000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	470000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2022	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	100000	usd
CY2021	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	100000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	382000000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	433600000	usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	273500000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	385400000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	547100000	usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	215000000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1900000	usd
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	900000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	248321000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1960000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	112420000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	1036000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	360741000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	2996000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	380690000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	470000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	380690000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	470000	usd
CY2022Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Position Amortized Cost DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost	363700000	usd
CY2021Q4	tvtx	Debt Securities Available For Sale Unrealized Loss Position Amortized Cost DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost	381200000	usd
CY2022Q1	tvtx	Debt Instrument Repurchase Amount Including Accrued And Unpaid Interest DebtInstrumentRepurchaseAmountIncludingAccruedAndUnpaidInterest	213800000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7600000	usd
CY2022	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	3400000	usd
CY2022	us-gaap	Interest Expense InterestExpense	11300000	usd
CY2021	us-gaap	Interest Expense InterestExpense	20100000	usd
CY2020	us-gaap	Interest Expense InterestExpense	19100000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	61688000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	388557000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	450245000	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	71200000	usd
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	71200000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	165753000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	387129000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	552882000	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	67100000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	67100000	usd
CY2022	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	2	business
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	302935000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	158833000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	144102000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	283557000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	136058000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	147499000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	30964000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	24946000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22437000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	33015000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	25793000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	19999000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	18129000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	18129000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	29037000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	144102000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	900000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	900000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	35267000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	25998000	usd
CY2022Q4	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	26070000	usd
CY2021Q4	tvtx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	26841000	usd
CY2022Q4	tvtx	Sales Discounts Rebates And Allowances Current SalesDiscountsRebatesAndAllowancesCurrent	13486000	usd
CY2021Q4	tvtx	Sales Discounts Rebates And Allowances Current SalesDiscountsRebatesAndAllowancesCurrent	7493000	usd
CY2022Q4	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	8791000	usd
CY2021Q4	tvtx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3144000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7755000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8402000	usd
CY2022Q4	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4373000	usd
CY2021Q4	tvtx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	3302000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	95742000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	75180000	usd
CY2022	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	36300000	usd
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022	tvtx	Common Stock Voting Rights Number Of Votes CommonStockVotingRightsNumberOfVotes	1	vote
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	5079000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5488207	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.37
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M9D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	46626000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6011349	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.34
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M28D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	71063000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6999669	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	20.22
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y7M13D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	21806000	usd
CY2022Q4	us-gaap	Share Price SharePrice	21.03
CY2021Q4	us-gaap	Share Price SharePrice	31.04
CY2020Q4	us-gaap	Share Price SharePrice	27.25
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	39177000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30766000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23614000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63758515	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63758515	shares
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-278482000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-278482000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.37
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.37
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59832287	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59832287	shares
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-180091000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-180091000	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.01
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.01
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47539631	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47539631	shares
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-169431000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-169431000	usd
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.56
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.56
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23085349	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17897060	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16830808	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-278169000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-179682000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-188790000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-19436000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	314000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	412000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	74000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-1000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-3000	usd
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	3000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	313000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	409000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-19359000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	313000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	409000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-19359000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0346
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0271
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0157
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0096
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0328
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0665
CY2022	tvtx	Effective Income Tax Rate Reconciliation In Process Research And Development Percent EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentPercent	0
CY2021	tvtx	Effective Income Tax Rate Reconciliation In Process Research And Development Percent EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentPercent	0
CY2020	tvtx	Effective Income Tax Rate Reconciliation In Process Research And Development Percent EffectiveIncomeTaxRateReconciliationInProcessResearchAndDevelopmentPercent	-0.0650
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Domestic EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Domestic EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements Domestic EffectiveIncomeTaxRateReconciliationTaxSettlementsDomestic	-0.0162
CY2022	tvtx	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent	-0.0049
CY2021	tvtx	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent	-0.0048
CY2020	tvtx	Effective Income Tax Rate Reconciliation Nondeductible Expense Executive Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExecutiveCompensationPercent	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.0020
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.0019
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2022	tvtx	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	-0.0020
CY2021	tvtx	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	-0.0015
CY2020	tvtx	Effective Income Tax Rate Reconciliation Other Permanent Differences EffectiveIncomeTaxRateReconciliationOtherPermanentDifferences	-0.0009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0665
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.1087
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0449
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0021
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0242
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0488
CY2022	tvtx	Effective Income Tax Rate Reconciliation Net Operating Loss Carryback Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackPercent	0
CY2021	tvtx	Effective Income Tax Rate Reconciliation Net Operating Loss Carryback Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackPercent	0
CY2020	tvtx	Effective Income Tax Rate Reconciliation Net Operating Loss Carryback Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossCarrybackPercent	0.0958
CY2022	tvtx	Effective Income Tax Rate Reconciliation Adoption Of Asu202006 EffectiveIncomeTaxRateReconciliationAdoptionOfASU202006	0.0421
CY2021	tvtx	Effective Income Tax Rate Reconciliation Adoption Of Asu202006 EffectiveIncomeTaxRateReconciliationAdoptionOfASU202006	0
CY2020	tvtx	Effective Income Tax Rate Reconciliation Adoption Of Asu202006 EffectiveIncomeTaxRateReconciliationAdoptionOfASU202006	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0020
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0010
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3419
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2809
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0675
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0011
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0023
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1025
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	49811000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	38618000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	91052000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	69213000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	36442000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	tvtx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	18124000	usd
CY2021Q4	tvtx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	16726000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	13247000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	8678000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	22936000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	18003000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	4781000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	3427000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	51391000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	48801000	usd
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	4346000	usd
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	2802000	usd
CY2022Q4	tvtx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	8018000	usd
CY2021Q4	tvtx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	8825000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	105000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	13000	usd
CY2022Q4	tvtx	Deferred Tax Assets Difference In Basis Of Loan Costs DeferredTaxAssetsDifferenceInBasisOfLoanCosts	15000	usd
CY2021Q4	tvtx	Deferred Tax Assets Difference In Basis Of Loan Costs DeferredTaxAssetsDifferenceInBasisOfLoanCosts	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	300268000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	215106000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	6658000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	5782000	usd
CY2022Q4	tvtx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	0	usd
CY2021Q4	tvtx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	11020000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	206000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6864000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16802000	usd
CY2022Q4	tvtx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	293404000	usd
CY2021Q4	tvtx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	198304000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	293404000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	198304000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	293400000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	95100000	usd
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	50500000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11500000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	11500000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7825000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5193000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2056000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2255000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	310000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1919000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	377000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11490000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7825000	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	100000	usd
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	100000	usd
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2100000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1300000	usd
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1200000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14244000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14154000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5195000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3048000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9049000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11106000	usd
CY2022	us-gaap	Depreciation Depreciation	2100000	usd
CY2021	us-gaap	Depreciation Depreciation	1700000	usd
CY2020	us-gaap	Depreciation Depreciation	2100000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6314000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6501000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6673000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6889000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	7064000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4781000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	38222000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	6279000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	31943000	usd
CY2022Q4	tvtx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	5575000	usd
CY2022Q4	tvtx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	5368000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21000000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0648
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0647
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	5000000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	4900000	usd
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	2000000	usd

Files In Submission

Name	View Source	Status
0001438533-23-000008-index-headers.html	Edgar Link	pending
0001438533-23-000008-index.html	Edgar Link	pending
0001438533-23-000008.txt	Edgar Link	pending
0001438533-23-000008-xbrl.zip	Edgar Link	pending
ex1012-1231202210k.htm	Edgar Link	pending
ex1037-1231202210k.htm	Edgar Link	pending
ex1039-1231202210k.htm	Edgar Link	pending
ex211-1231202210k.htm	Edgar Link	pending
ex231-1231202210k.htm	Edgar Link	pending
ex311-1231202210k.htm	Edgar Link	pending
ex312-1231202210k.htm	Edgar Link	pending
ex321-1231202210k.htm	Edgar Link	pending
ex322-1231202210k.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tvtx-20221231.htm	Edgar Link	pending
tvtx-20221231.xsd	Edgar Link	pending
tvtx-20221231_g1.jpg	Edgar Link	pending
tvtx-20221231_g2.jpg	Edgar Link	pending
tvtx-20221231_def.xml	Edgar Link	unprocessable
tvtx-20221231_lab.xml	Edgar Link	unprocessable
tvtx-20221231_pre.xml	Edgar Link	unprocessable
tvtx-20221231_htm.xml	Edgar Link	completed
tvtx-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics, Inc. Stock $tvtx

2023 Q1 Form 10-K Financial Statement

#000143853323000008 Filed on February 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics, Inc. Stock $tvtx

2023 Q1 Form 10-K Financial Statement

#000143853323000008 Filed on February 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics, Inc. Stock $tvtx